11th Invitation to Manufacturers of Reproductive Health Medicines to Submit an Expression of Interest (EOI) for Product Evaluation by the WHO Expert Review Panel (ERP) for Reproductive Health Medicine
UNFPA
11th Invitation to Manufacturers of Reproductive Health Medicines to Submit an Expression of Interest (EOI) for Product Evaluation by the WHO Expert Review Panel (ERP) for Reproductive Health Medicine
Request for EOI
Reference:
ERP for Reproductive Health Medicines, UNFPA/DNK/EOI/17/012
Beneficiary countries:
Multiple destinations (see 'Countries' tab below)
Published on:
24-Apr-2017
Deadline on:
15-Jun-2017 17:00 (GMT 2.00)
Description
11th Invitation to Manufacturers of Reproductive Health Medicines to Submit an Expression of Interest (EOI) for Product Evaluation by the WHO Expert Review Panel (ERP) for Reproductive Health Medicines
Seloi Mogatle - mogatle@unfpa.org, Tel: +45 45337277
Email:
mogatle@unfpa.org
First name:
Seloi
Surname:
Mogatle
Telephone country code:
Denmark (+45)
Telephone number:
45337277
51181578
-
Dapagliflozin
51181579
-
Empagliflozin
51181604
-
Thyroid-stimulating hormone or thyrotropin or thyrotropin alfa
51181605
-
Methimazole
51181606
-
Propylthiouracil
51181608
-
Levothyroxine or thyroxine or triiodothyronine
51181613
-
Calcitonin
51181614
-
Carbimazole
51181625
-
Calcitonin salmon
51181629
-
Levothyroxine sodium
51181901
-
Choriogonadotropin alfa or chorionic gonadotropin
51181912
-
Follitropin or follitropin alfa and follitropin beta
51181927
-
Clomifene citrate
51181931
-
Lutropin (LH)/Follitropin (FSH)
51181932
-
Lutropin alfa
51182002
-
Testosterone
51182014
-
Dutasteride
51182024
-
Danazol
51182027
-
Flutamide
51182035
-
Nilutamide
51182047
-
Tibolone
51182071
-
Testosterone enanthate
51182101
-
Desmopressin
51182102
-
Argipressin or vasopressin
51182106
-
Terlipressin
51182108
-
Desmopressin acetate
51182201
-
Dinoprostone
51182202
-
Methylergometrine or methylergonovine
51182203
-
Oxytocin
51182206
-
Atosiban
51182207
-
Carbetocin
51182214
-
Misoprostol
51182222
-
Ergometrine maleate
51182302
-
Human growth hormone or somatotropin or somatropin
51182406
-
Alendronic acid or alendronate sodium
51182415
-
Zoledronic acid
51182417
-
Risedronate sodium or risedronic acid
51182426
-
Cinacalcet
51182428
-
Denosumab
51182435
-
Teriparatide
51182441
-
Cholecalciferol/Risedronate sodium or risedronic acid
51182501
-
Levothyroxine/liothyronine
51182709
-
Metformin/sitagliptin
51182710
-
Metformin/linagliptin
51182711
-
Glimepiride/metformin
51183301
-
Linagliptin
51183303
-
Sitagliptin
51183306
-
Sitagliptin phosphate
51183505
-
Metformin
51183510
-
Metformin hydrochloride
51183601
-
Exenatide
51183603
-
Insulin
51183607
-
Insulin aspart
51183608
-
Insulin beef
51183610
-
Insulin glargine
51183611
-
Liraglutide
51183613
-
Insulin glulisine
51183614
-
Insulin human
51183615
-
Insulin lispro
51183622
-
Insulin aspart/Insulin aspart protamine
51183623
-
Insulin degludec
51183706
-
Pioglitazone hydrochloride
51183801
-
Acarbose
51184004
-
Glibenclamide or glyburide
51184007
-
Gliclazide
51351509
-
Medroxyprogesterone
51351510
-
Megestrol
51351511
-
Megestrol acetate
51351514
-
Progesterone
51351605
-
Estradiol or oestradiol
51351606
-
Dienogest
51351608
-
Estriol
51351609
-
Fulvestrant
51351612
-
Medroxyprogesterone acetate
51351613
-
Mifepristone
51351627
-
Estradiol valerate
51351635
-
Conjugated estrogens/medroxyprogesterone acetate
51351636
-
Estradiol/trimegestone
51351637
-
Estradiol cypionate/medroxyprogesterone acetate
51351804
-
Estrogens conjugated
51351912
-
Ulipristal acetate
51352005
-
Etonogestrel
51352006
-
Levonorgestrel
51352008
-
Norethindrone or norethisterone
51352404
-
Drospirenone/estradiol
51352413
-
Ethinyl estradiol/levonorgestrel
51352414
-
Ethinyl estradiol/norelgestromin
51352422
-
Desogestrel and ethinyl estradiol
51352426
-
Estradiol/norethindrone
51352435
-
Cyproterone/Estradiol + Estradiol
51352436
-
Ethinylestradiol/cyproterone acetate
11th Invitation to Manufacturers of Reproductive Health Medicines to Submit an Expression of Interest (EOI) for Product Evaluation by the WHO Expert Review Panel (ERP) for Reproductive Health Medicines
Instead of
10th Invitation to Manufacturers of Reproductive Health Medicines to Submit an Expression of Interest (EOI) for Product Evaluation by the WHO Expert Review Panel (ERP) for Reproductive Health Medicines
Edited on:
24-Apr-2017 14:21
Edited by:
palau@unfpa.org